Martinez A, Schray M F, Howes A E, Bagshaw M A
J Clin Oncol. 1985 Jul;3(7):901-11. doi: 10.1200/JCO.1985.3.7.901.
We updated 152 cases of epithelial ovarian cancer, International Federation of Gynecology and Obstetrics (FIGO) stages I through III, treated at the Stanford Medical Center (Stanford, Calif) with irradiation as the only postoperative therapy. In 133 patients, radiation was directed only to those regions of known disease, while it was delivered to the whole abdomen and pelvis by the Martinez technique in 19 patients. Mean follow-up time was 6.8 years. The results were analyzed as freedom from relapse (FFR) at 15 years; overall, FFR constituted 44% of the patients. Statistically significant differences of FFR appeared between stages II (60%) and III (16%); among the histopathologic variants endometrioid (64%), serous papillary (45%), and undifferentiated (7%); between pathologic grades 2 (68%) and 3 (20%); between amounts of postoperative residual disease less than 2 cm (48%) and greater than 2 cm (16%); and between ages less than 40 (80%) and greater than or equal to 40 (38%). Considering all stages and grades together, FFR in the 54 cases with unfavorable residuum (greater than 2 cm) was 14%. Among the 98 with favorable residuum (none, or less than 2 cm) FFR was 62%; and 14 (39%) of the 36 relapses were in the untreated upper abdomen. Results in the favorable group support effectiveness of irradiation as postoperative therapy. These patterns of relapse suggest that whole-abdominopelvic irradiation would further increase FFR. We believe that, for favorable disease as defined such radiotherapy should be the standard for comparison.
我们对斯坦福医疗中心(加利福尼亚州斯坦福)收治的152例国际妇产科联盟(FIGO)分期为I至III期的上皮性卵巢癌患者进行了更新,这些患者术后仅接受放疗。133例患者的放疗仅针对已知疾病区域,19例患者采用马丁内斯技术对全腹和盆腔进行放疗。平均随访时间为6.8年。结果分析为15年无复发生存率(FFR);总体而言,FFR占患者的44%。II期(60%)和III期(16%)之间的FFR存在统计学显著差异;在组织病理学类型中,子宫内膜样癌(64%)、浆液性乳头状癌(45%)和未分化癌(7%)之间存在差异;病理分级2级(68%)和3级(20%)之间存在差异;术后残留病灶小于2 cm(48%)和大于2 cm(16%)之间存在差异;年龄小于40岁(80%)和大于或等于40岁(38%)之间存在差异。综合考虑所有分期和分级,54例残留病灶不利(大于2 cm)患者的FFR为14%。98例残留病灶有利(无或小于2 cm)患者的FFR为62%;36例复发患者中有14例(39%)发生在未接受治疗的上腹部。有利组的结果支持放疗作为术后治疗的有效性。这些复发模式表明,全腹盆腔放疗将进一步提高FFR。我们认为,对于如此定义的有利疾病,这种放疗应作为比较的标准。